University of Minnesota. Driven to Discover.
Safety profile was good, and sensitivity analysis favored delamanid as part of MDR-TB treatment.
Whole-genome sequencing could lead to faster, more accurate resistance testing.
TB remains high in many low- and middle-income nations, and about 558,000 people in 2017 developed rifampicin-resistant TB.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.